Michael B Boffa
Overview
Explore the profile of Michael B Boffa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akinlonu A, Boffa M, Lyu C, Zhong J, Jindal M, Fadzan M, et al.
J Clin Lipidol
. 2025 Jan;
19(1):39-50.
PMID: 39828454
Background: Lipoprotein(a) [Lp(a)] is a driver of residual cardiovascular risk. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) decrease Lp(a) with significant heterogeneity in response. We investigated contributors to the heterogeneous...
2.
Bruwer D, de Lange-Loots Z, Koschinsky M, Boffa M, Pieters M
J Clin Lipidol
. 2024 Sep;
18(6):e1002-e1014.
PMID: 39306544
Background: Case-control, intervention and laboratory studies have demonstrated a link between apolipoprotein B (ApoB)-containing lipoproteins and clot structure and thrombosis. There is, however, limited evidence on a population level. Objectives:...
3.
Boffa M, Koschinsky M
Biochem J
. 2024 Sep;
481(19):1277-1296.
PMID: 39302109
Elevated plasma levels of lipoprotein(a) (Lp(a)) are a prevalent, independent, and causal risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease. Lp(a) consists of a lipoprotein particle resembling...
4.
Koschinsky M, Soffer D, Boffa M
J Clin Lipidol
. 2024 Sep;
18(6):e886-e892.
PMID: 39299825
This is an exciting time in the lipoprotein(a) [Lp(a)] field. Attention to this important lipoprotein and potent cardiovascular risk marker is transitioning from the purview of the specialist to that...
5.
Marar T, Boffa M
Res Pract Thromb Haemost
. 2024 Jul;
8(4):102459.
PMID: 38983903
Background: Thrombin-activatable fibrinolysis inhibitor (TAFI) is a plasma zymogen that provides a molecular link between coagulation and fibrinolysis. Studies have shown that the presence of glycosaminoglycans accelerates TAFI activation by...
6.
Madarati H, DeYoung V, Singh K, Sparring T, Kwong A, Fredenburgh J, et al.
Sci Rep
. 2024 Apr;
14(1):9073.
PMID: 38643218
ADAMTS13, a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13, regulates the length of Von Willebrand factor (VWF) multimers and their platelet-binding activity. ADAMTS13 is constitutively secreted...
7.
Koschinsky M, Bajaj A, Boffa M, Dixon D, Ferdinand K, Gidding S, et al.
J Clin Lipidol
. 2024 Apr;
18(3):e308-e319.
PMID: 38565461
Since the 2019 National Lipid Association (NLA) Scientific Statement on Use of Lipoprotein(a) in Clinical Practice was issued, accumulating epidemiological data have clarified the relationship between lipoprotein(a) [Lp(a)] level and...
8.
Garabon J, Boffa M
J Thromb Thrombolysis
. 2023 Jun;
56(2):283-290.
PMID: 37310666
Rivaroxaban is a direct factor Xa inhibitor, recently implemented as a favorable alternative to warfarin in anticoagulation therapy. Rivaroxaban effectively reduces thrombin generation, which plays a major role in the...
9.
Lorey M, Youssef A, Aikas L, Borrelli M, Hermansson M, Assini J, et al.
Front Cardiovasc Med
. 2023 Jun;
10:1130162.
PMID: 37293282
Introduction: Lipoprotein(a) (Lp(a)) is an LDL-like particle with an additional apolipoprotein (apo)(a) covalently attached. Elevated levels of circulating Lp(a) are a risk factor for atherosclerosis. A proinflammatory role for Lp(a)...
10.
Assini J, Clark J, Youssef A, Xing C, Doerfler A, Park S, et al.
Atherosclerosis
. 2023 Jun;
384:117150.
PMID: 37290980
Background And Aims: Despite increased clinical interest in lipoprotein(a) (Lp(a)), many questions remain about the molecular mechanisms by which it contributes to atherosclerotic cardiovascular disease. Existing murine transgenic (Tg) Lp(a)...